Novo Nordisk announced a new analysis of phase 3 data demonstrating people with hemophilia A who had the highest annualized bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment. Data for the recombinant factor VIII (rFVIII) product NovoEight®were presented at the 56th Annual Meeting of the American Society of Hematology (ASH).
The post hoc analysis from the guardian™2 trial further found that, when continued on treatment with NovoEight®, adults and adolescents showed reductions of 69 percent and 63 percent , respectively, in ABR compared with their ABRs from guardian™1.
“This post hoc analysis gives an indication that patients with high baseline bleed rate can benefit from prophylaxis with NovoEight®, as well as patients who maintain low ABR,” said Margareth Ozelo, M.D., Ph.D., Hemocentre, IHTC, University of Campinas, Sao Paulo, Brazil, and lead investigator.
